Research Article
The Role of Tumor-Infiltrating B Cells in Tumor Immunity
Table 1
TIB and prognosis of cancer patients.
| | Tumor type | Related mechanism | Prognostic evaluation |
| | Breast cancer | | TLS formation, CD20+ TIB, IBC and TN IBC: CD20+ TIL/PD-L1+ TIL | Good | | | | DCIS: CD20+ TIB | Bad | | Node-negative breast cancer | Unrelated |
| | Ovarian cancer | | High-grade serous ovarian tumor: correlation of antigen-experienced but atypical CD27–CD20+ TIL and CD8+ T cell | Good | | CD138highCD20+ TIB | Bad |
| | Melanoma | | TLS formation, high CD20+ TIB, expression of CD20+ TIB in close proximity to CD3+ T cells | Good | | Cutaneous melanoma: high CD20+ TIB, CD138+ plasma cells | Bad |
| | Colorectal cancer | TLS formation, CD20+, CD138+, IGKC+ tumor-infiltrating B cells and plasma cells | Good |
| | Gastric cancer | TLS formation | Good |
| | Bladder cancer | MIBC: CD19+ TIB serve as APC to activate CD4+ TIT | Good |
| | Prostate cancer | Higher TIB | Bad |
| | Lung cancer | | Adenocarcinoma: CD138+ plasma cells, IGKC+ | Good | | NSCLC: CD20+ B cells and CD79α+p63+ plasma cells | Bad | | NSCLC | Unrelated |
| | Liver cancer | TLS formation | Good | | HCC: synergistic effect of CD20+ TIB and CD8+ T cell | |
|
|
Special tumor subtypes are shown in bold.
|
